Read on Twitter
1/13
In Aug 2020 LG Chem expanded their +$300m deal with #AVCT, to include Avacta’s Affimer XTTM technology, adding over $100m in 'potential' milestone payments.
This deal was effectively lost to the whole AVCT is Covid news or nothing else noise.
https://twitter.com/BigBiteNow/status/1361975961563127808?s=20
In Aug 2020 LG Chem expanded their +$300m deal with #AVCT, to include Avacta’s Affimer XTTM technology, adding over $100m in 'potential' milestone payments.
This deal was effectively lost to the whole AVCT is Covid news or nothing else noise.
https://twitter.com/BigBiteNow/status/1361975961563127808?s=20
2/
Investors should be asking themselves, why after nearly 2 years of working with AVCT, on the development of two different Affimer® PK/ADME modifiers, they returned to AVCT to expand their deal, for technology,
Investors should be asking themselves, why after nearly 2 years of working with AVCT, on the development of two different Affimer® PK/ADME modifiers, they returned to AVCT to expand their deal, for technology,
3/
"which can be used to control the time a drug spends in the circulation."
If this now +$400m deal wasn't demonstrating to LG Chem worthwhile progress, then why come back? Particularly, in the middle of a Covid pandemic, that was reportedly,
"which can be used to control the time a drug spends in the circulation."
If this now +$400m deal wasn't demonstrating to LG Chem worthwhile progress, then why come back? Particularly, in the middle of a Covid pandemic, that was reportedly,
4/
swallowing up all available resources.
I am abundantly aware that the focus is on Covid tests and their sales, with many even nailing it down to UK Gov contracts. I get that but its wrong to simply take potential Covid revenues and then decide a simple valuation for AVCT,
swallowing up all available resources.
I am abundantly aware that the focus is on Covid tests and their sales, with many even nailing it down to UK Gov contracts. I get that but its wrong to simply take potential Covid revenues and then decide a simple valuation for AVCT,
5/
as a Covid stock because those cash flows, feed into so much more then that result.
Its even worse, to throw AVCT into the Covid stock bucket because its the tech that wins here, not the Covid tests, be it that their technical success is critical.
as a Covid stock because those cash flows, feed into so much more then that result.
Its even worse, to throw AVCT into the Covid stock bucket because its the tech that wins here, not the Covid tests, be it that their technical success is critical.
6/
Of course, if I can have both, i will gladly take them but as I have said for a long time now, I am long term AVCT and I first and foremost want to see the tech proved up and with it, far better acceptance in the industry.
Then I want to see healthy sales, that gives AVCT,
Of course, if I can have both, i will gladly take them but as I have said for a long time now, I am long term AVCT and I first and foremost want to see the tech proved up and with it, far better acceptance in the industry.
Then I want to see healthy sales, that gives AVCT,
7/
the necessary firepower, to expand into what will be, vastly stronger opportunities, led by tech success.
AVCT has already demonstrated a slice of where it wants to head, by raising c. £50m in June 2020 and expanding the diagnostics platform, to cope with in-house...
the necessary firepower, to expand into what will be, vastly stronger opportunities, led by tech success.
AVCT has already demonstrated a slice of where it wants to head, by raising c. £50m in June 2020 and expanding the diagnostics platform, to cope with in-house...
8/
development + commencing a wider therapeutics programme, which is just the tip of the iceberg, compared to what significant cash flows will do, if/when AVA6000, demonstrates the wider opportunity is real.
That value, in this sector, is multiples of what we have today.
development + commencing a wider therapeutics programme, which is just the tip of the iceberg, compared to what significant cash flows will do, if/when AVA6000, demonstrates the wider opportunity is real.
That value, in this sector, is multiples of what we have today.
9/
So simply measuring potential Covid sales or indeed employing 'competition,' as a means to value AVCT, is so fundamentally wrong, it pains me to read it.
AVCT has multiple deals, such as the one above or indeed Daewoong, which are only going to get better, once
So simply measuring potential Covid sales or indeed employing 'competition,' as a means to value AVCT, is so fundamentally wrong, it pains me to read it.
AVCT has multiple deals, such as the one above or indeed Daewoong, which are only going to get better, once
10/
the tech is proven and the cash flows are there, that enable stronger deals to be made, or better still, more programmes brough in-house.
A clear demonstration of this policy was shown through the £50m fund raise last June. It was reinforced by the Q&A answer in the...
the tech is proven and the cash flows are there, that enable stronger deals to be made, or better still, more programmes brough in-house.
A clear demonstration of this policy was shown through the £50m fund raise last June. It was reinforced by the Q&A answer in the...
11/
Sept interims, where it was made clear that strong cash flows, could/would enable AVCT, to take their therapeutic programmes further on their own.
I am sure that further plans exist and will be implemented, as cash flows are solidified in the coming months.
Sept interims, where it was made clear that strong cash flows, could/would enable AVCT, to take their therapeutic programmes further on their own.
I am sure that further plans exist and will be implemented, as cash flows are solidified in the coming months.
12/
Investors can come back to me with the whole AVCT is valued purely on its Covid tests debate but its of little interest to my long term view +
some investors grossly underestimate what recurring revenues that avoid fund raises ad open up wider programmes,
Investors can come back to me with the whole AVCT is valued purely on its Covid tests debate but its of little interest to my long term view +
some investors grossly underestimate what recurring revenues that avoid fund raises ad open up wider programmes,
13/
means to a pharma play, introducing new tech, that they are successfully proving works and works really well, in the applications it is applied towards.
means to a pharma play, introducing new tech, that they are successfully proving works and works really well, in the applications it is applied towards.
